29th March 2022 | Pharma Updates
India adds 1,270 additional COVID-19 cases, bringing the active cases decline to 15,859 cases
COVID-19 immunisation coverage in India has surpassed 183.26 crore people. This was accomplished by a total of 2,17,89,216 sessions.
Drug-resistant TB strains can also be identified through genome sequencing
The network of genome sequencing labs in India, which is now looking for SARS-CoV-2 mutations, can also be used to detect drug-resistant tuberculosis bacteria (TB).
FDA placed restrictions on the use of GSK and Vir's COVID-19 antibody therapy
FDA has revised its Emergency Use Authorization (EUA) for GlaxoSmithKline and Vir Biotechnology’s sotrovimab for COVID-19. The change is exclusive to the BA.2 Omicron sub-variant.
FDA approved UCB's medication for uncommon childhood epilepsy
UCB SA, a Belgian biotech business, announced on Monday that the USFDA had approved its drug to treat seizures linked with Lennox-Gastaut Syndrome (LGS), a rare form of childhood epilepsy.
Second immunization booster considerably reduces COVID death rates
As per study in Israel, senior individuals who received a second booster of the Pfizer–BioNTech COVID-19 immunisation had a 78% reduced mortality rate from the disease than those who had only one.
FDA has approved the expansion of the Prima System US feasibility study to Stanford Medicine
Pixium Vision, a bioelectronics firm, has announced that the USFDA has approved the expansion of the Prima System US feasibility study to include Stanford Medicine as a trial site.
Staar Surgical's implantable collamer lenses have been approved by the FDA
FDA has approved the EVO/EVO+ Visian Implantable Collamer Lens (“EVO”) by Staar Surgical Co. for the correction of myopia and myopia with astigmatism.
FDA notifies Zandelisib developers of the need for randomized phase 3 Trial for Approval
Following a discussion with FDA over the approval of zandelisib for B-cell malignancies, drug developers will focus on the randomised phase 3 COASTAL trial.
Novo Nordisk received FDA approval for higher-dose Ozempic formulation
Novo Nordisk announced that the USFDA has approved a 2 mg dose of Ozempic injection, a once-weekly glucagon-like peptide-1 analog indicated in adults with type 2 diabetes.
Sanofi's rare disease drug receives world-first approval in Japan
Sanofi has released the world’s first medication for the rare disease Niemann-Pick type A/B and B in Japan and wants to secure approvals for the medicine in the US and Europe before the end of the year.